Maja J. A. de Jonge

Learn More
This phase I, open-label, dose-escalation study assessed the maximum-tolerated dose, safety, pharmacokinetics, and preliminary antitumor activity of pazopanib plus lapatinib combination therapy in patients with solid tumors. Patients were to take pazopanib and lapatinib orally once daily in a fasting condition. During the escalation phase, pazopanib and(More)
Purpose The pan-Class I PI3K inhibitor buparlisib (BKM120) has shown activity in a range of preclinical cancer models. This first-in-man study was initiated to identify the maximum tolerated dose (MTD) of buparlisib (100 mg/day) and to assess safety and preliminary efficacy. Methods Patients with advanced solid tumors (N = 83) enrolled in a Phase I(More)
Background: The purpose of this study was to look at the pharmacokinetics of docetaxel, cisplatin-derived platinum and 5-fluorouracil (5-FU), when used in combination, to exclude potential clinically relevant pharmacokinetic interactions. Methods: Fifteen patients with recurrent or metastatic solid tumors were randomized to receive docetaxel 75 mg/m2 and(More)
This study was designed to evaluate irinotecan (CPT11) disposition and pharmacodynamics in the presence and absence of the broad-spectrum antibiotic neomycin. Seven evaluable cancer patients experiencing diarrhea graded >2 after receiving CPT-11 alone (350 mg/m i.v. once every 3 weeks) received the same dose combined with oral neomycin at 1000 mg three(More)
The renewed interest in topoisomerase 1 inhibitors, based on newinsights on the mechanism of action and the development of semi-synthetic derivates of camptothecin with a more favourable toxicityprofile, has led to extensive preclinical and clinical research.Significant levels of anti-tumor activity in human tumor xenograftswere seen especially with(More)
Both weekly cisplatin chemotherapy and single agent topotecan have proven to be effective in recurrent ovarian cancer. Preclinical data show synergism between cisplatin and topotecan. Side effects for this combination are drug sequence dependent and predominantly haematologic. Since preclinical data suggest that Cremophor EL (CrEL), the formulation vehicle(More)
There are several reasons why combining an inhibitor of the vascular endothelial and the platelet-derived growth factor receptor with a taxane might induce synergistic antitumor activity. This phase I study aimed to determine the maximal tolerated dose (MTD) of the combination of pazopanib with two different schedules of docetaxel. In a 3 + 3 + 3 design,(More)
system (BPMS) built for the Intersecting Storage Rings For calibration purposes it is necessary to adjust (ISR) of CERN,, as used during the present running-in the electrode capacity to ground, For BPMS accuracy, period. This beam observation is based on the direct the electrode capacity must be very stable and balanced viewing of beam signals which permit(More)
Several emotional responses may be invoked in critical care physicians when confronted with selective decontamination of the digestive tract (SDD). Although recent meta-analyses have shown that the use of SDD reduces the occurrence of ventilator-associated pneumonia and improves ICU survival, the effectiveness of SDD has remained controversial. We recently(More)
  • 1